Cancers (Oct 2022)

Utilization Trend and Comparison of Different Radiotherapy Modes for Patients with Early-Stage High-Intermediate-Risk Endometrial Cancer: A Real-World, Multi-Institutional Study

  • Kang Ren,
  • Lijuan Zou,
  • Tiejun Wang,
  • Zi Liu,
  • Jianli He,
  • Xiaoge Sun,
  • Wei Zhong,
  • Fengju Zhao,
  • Xiaomei Li,
  • Sha Li,
  • Hong Zhu,
  • Zhanshu Ma,
  • Shuai Sun,
  • Wenhui Wang,
  • Ke Hu,
  • Fuquan Zhang,
  • Xiaorong Hou,
  • Lichun Wei

DOI
https://doi.org/10.3390/cancers14205129
Journal volume & issue
Vol. 14, no. 20
p. 5129

Abstract

Read online

This study aimed to compare the outcomes of RT modalities among patients who met different HIR criteria based on multicentric real-world data over 15 years. The enrolled patients, who were diagnosed with FIGO I-II EC from 13 medical institutes and treated with hysterectomy and RT, were reclassified into HIR groups according to the criteria of GOG-249, PORTEC-2, and ESTRO-ESMO-ESGO, respectively. The trends in RT modes utilization were reviewed using the Man-Kendall test. The rate of VBT alone increased from zero in 2005 to 50% in 2015, which showed a significant upward trend (p p > 0.05). There were no significant differences in OS, DFS, LRFS, and DMFS between VBT alone and EBRT ± VBT in three HIR cohorts. Subgroup analyses in the GOG-249 HIR cohort showed that EBRT ± VBT had higher 5-year DFS, DMFS, and LRFS than VBT alone for patients without lymph node dissection (p < 0.05). Thus, VBT could be regarded as a standard adjuvant radiation modality for HIR patients. EBRT should be administrated to selected HIR patients who meet the GOG-249 criteria and did not undergo lymph node dissection.

Keywords